Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

Trial Status: active

This clinical trial investigates the use of [13C]pyruvate as an imaging agent for MRI scans. [13C]pyruvate is a natural sugar found in your body, but it can also be given to people by injection into a vein as an imaging agent for MRI scans. When [13C]pyruvate moves throughout the body after injection, chemical reactions in the body’s cells change the sugar into energy (a process called metabolism). As [13C]pyruvate is metabolized, it shows up in the images made with MRI scans. Researchers think [13C]pyruvate could be especially useful for imaging cancer. This is because MRI scans using [13C]pyruvate can detect small amounts of cancer as the imaging agent is metabolized in cancer cells. In addition, [13C]pyruvate causes few side effects and does not expose people to radiation. Many imaging agents given to cancer patients are radioactive (give off radiation as they travel throughout the body). Information from this study may help researchers learn more about how the imaging agent is distributed in healthy organs and tissues, and may help change approaches to MRI imaging in cancer patients.